The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Håkan Axelson

Håkan Axelson

Research team manager

Håkan Axelson

Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.

Author

  • Kristoffer von Stedingk
  • Katleen De Preter
  • Jo Vandesompele
  • Rosa Noguera
  • Ingrid Øra
  • Jan Koster
  • Rogier Versteeg
  • Sven Påhlman
  • David Lindgren
  • Håkan Axelson

Summary, in English

Several gene expression-based prognostic signatures have been described in neuroblastoma, but none have successfully been applied in the clinic. Here we have developed a clinically applicable prognostic gene signature, both with regards to number of genes and analysis platform. Importantly, it does not require comparison between patients and is applicable amongst high-risk patients. The signature is based on a two-gene score (R-score) with prognostic power in high-stage tumours (stage 4 and/or MYCN-amplified diagnosed after 18 months of age). QPCR-based and array-based analyses of matched cDNAs confirmed cross platform (array-qPCR) transferability. We also defined a fixed cut-off value identifying prognostically differing subsets of high-risk patients on an individual patient basis. This gene expression signature independently contributes to the current neuroblastoma classification system, and if prospectively validated could provide further stratification of high-risk patients, and potential upfront identification of a group of patients that are in need of new/additional treatment regimens.

Department/s

  • Kidney cancer research group
  • Division of Translational Cancer Research
  • Paediatrics (Lund)
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publishing year

2015

Language

English

Pages

868-877

Publication/Series

International Journal of Cancer

Volume

137

Issue

4

Document type

Journal article

Publisher

John Wiley & Sons Inc.

Topic

  • Cancer and Oncology

Status

Published

Research group

  • Kidney cancer research group

ISBN/ISSN/Other

  • ISSN: 0020-7136